Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF + Lomustine in Glioblastoma
NCT05304663Phase 1Withdrawn
- Sponsor
- Philogen
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
01
Overview
Phase 1, open-label trial of onfekafusp alfa in glioblastoma (GBM) (2 arms), sponsored by Philogen. Primary endpoint: Safety of L19TNF plus lomustine with different administration sequences. Planned start Jun 2022; status: withdrawn.
02
Drugs
onfekafusp alfa
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05304663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304663.